[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"precision-therapy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:precision-therapy":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,42,67],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100527249","phase-2-precision-treatment-of-recurrentmetastatic-salivary-gland-carcinoma-guided-by-molecular-typing-100527249",false,"NCT06145308","Precision Treatment of Recurrent\u002FMetastatic Salivary Gland Carcinoma Guided by Molecular Typing","Cancer Hospital, Chinese Academy of Medical Sciences\u002FNational Cancer Center of China","Inclusion Criteria:\n\n* Patients with histopathologic diagnosis of salivary gland carcinoma\n\n  * The tumor tissues were subjected to HER2\u002FNTRK\u002FAR\u002FTROP-2 immunohistochemical staining.\n\n    * ECOG physical status 0 or 1 score in the 3 days before the first medication of the study treatment;\n\n      * Age 18 or older - no upper limit;\n\n        * Life expectancy is more than 3 months; ⑥Have at least one measurable lesion according to RECIST1.1 standards; ⑦Women of childbearing age must have a negative pregnancy test within 7 days before the first medication, and agree to receive the necessary contraceptive measures;\n\n          ⑧The patient must have adequate liver, kidney, bone marrow, heart and lung and other organ functions:\n\n          ⑨Understanding and voluntarily signing informed consent prior to performing any research-related evaluation\u002Foperation;\n\n          ⑩Ability to comply with research visit schedules and other programmatic requirements.\n\nExclusion Criteria:\n\n* Known hypersensitivity or delayed anaphylaxis to any agents in this trial;\n\n  * Major surgery had been performed within 4 weeks prior to the start of the study and did not fully recover;\n\n    * Have received a live vaccine within 4 weeks before the start of the study or plan to receive any vaccine during the study period ;\n\n      * To study the occurrence of arterial\u002Fvenous thrombosis events within 6 months before medication;\n\n        * Major cardiovascular diseases;\n\n          * Is suffering from uncontrolled systemic diseases, including diabetes, hypertension, pulmonary fibrosis, acute lung disease, interstitial lung disease, cirrhosis, etc.;\n\n            * Is suffering from an active infection that requires systemic treatment;\n\n              * History of active tuberculosis; ⑨ Positive human immunodeficiency virus (HIV) test result; ⑩ Patients with chronic hepatitis B or active hepatitis C. ⑪Conditions that the investigator believes will affect the safety or compliance of the drug therapy in this study ⑫Female\u002Fmale who is pregnant or breastfeeding or who intends to give birth;","ALL","18 Years","100 Years",{"count":20,"type":21},39,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","Patients with salivary gland carcinoma were divided into groups according to HER2, NTRK, AR, TROP-2, etc. Patients in different groups were given precision targeted therapy or chemotherapy to evaluate the efficacy (ORR rate) and safety of precision therapy.",[27,28],"Salivary Gland Carcinoma","Precision Therapy","RECRUITING","2026-03-27",{"date":32,"type":33},"2026-04-02","ACTUAL",{"date":35,"type":33},"2023-08-15",{"date":37,"type":21},"2028-07-10",{"name":39,"class":40},"Peking Union Medical College","OTHER",2,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":49,"enrollmentInfo":50,"targetDuration":4,"studyType":22,"phases":52,"briefSummary":54,"conditions":55,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":66},"100551696","phase-1-precision-treatment-of-unresectable-hcc-guided-by-multi-omics-deep-learning-models-100551696","NCT06463444","Precision Treatment of Unresectable HCC Guided by Multi-omics Deep Learning Models","Precision Treatment of Unresectable Liver Cancer Based on Multi-omics Deep Learning Model: a Multi-center Prospective Single-arm Study","Inclusion Criteria:\n\n1. Aged 18-75.\n2. No previous local or systemic treatment for hepatocellular carcinoma.\n3. Child-Pugh liver function score ≤ 7.\n4. ECOG PS 0-1.\n5. No serious organic diseases of the heart, lungs, brain, kidneys, etc.\n6. Enhanced MRI determines that the tumor is technically unresectable.\n7. Pathologic type of hepatocellular carcinoma confirmed by puncture biopsy.\n8. Multimodal Deep Learning Model Screening Based on Pathology, Imaging, and Genetic Data Suggests Benefit from HAIC in Combination with Lenvatinib and PD-1 inhibitors.\n\nExclusion Criteria:\n\n1. Pregnant and lactating women.\n2. Suffering from a condition that interferes with the absorption, distribution, metabolism, or clearance of the study drug (e.g., severe vomiting, chronic diarrhea, intestinal obstruction, impaired absorption, etc.).\n3. A history of gastrointestinal bleeding within the previous 4 weeks or a definite predisposition to gastrointestinal bleeding (e.g., known locally active ulcer lesions, fecal occult blood ++ or more, or gastroscopy if persistent fecal occult blood +) that has not been targeted, or other conditions that may have caused gastrointestinal bleeding (e.g., severe fundoplication\u002Fesophageal varices), as determined by the investigator.\n4. Active infection.\n5. Other significant clinical and laboratory abnormalities that affect the safety evaluation.\n6. Inability to follow the study protocol for treatment or follow up as scheduled.","75 Years",{"count":51,"type":21},30,[53],"PHASE1","Surgery is the main curative treatment for hepatocellular carcinoma(HCC) patients, but 70%-80% of HCC patients are in the middle and advanced stages at the time of diagnosis and cannot be surgically resected. Local and systemic therapy are the main treatments for unresectable HCC. Two recent trials of HAIC combined with PD-1 monoclonal antibody and targeted therapy reported objective response rates (ORR) as high as 43.3% to 77.1%.",[56,28],"HCC","2024-06-12",{"date":59,"type":33},"2024-06-17",{"date":61,"type":33},"2024-06-01",{"date":63,"type":21},"2026-06-30",{"name":65,"class":40},"Chen Xiaoping",1,{"id":68,"slug":69,"hasResults":11,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":73,"eligibilityCriteria":74,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":75,"targetDuration":4,"studyType":22,"phases":77,"briefSummary":78,"conditions":79,"keywords":89,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":41},"100539700","phase-1-precision-therapy-for-solid-tumors-synergistic-cdk46-inhibition-and-anti-vegf-targeting-lncrna-100539700","NCT06307249","Precision Therapy for Solid Tumors: Synergistic CDK4\u002F6 Inhibition and Anti-VEGF Targeting LncRNA","Precision Therapy for Solid Tumors: Synergistic Inhibition of Cell Proliferation and Angiogenesis Via CDK4\u002F6 and Anti-VEGF Approach Targeting LncRNA Expression","PTST_PALBEVA","Inclusion Criteria:\n\n* Individuals of white ethnicity.\n* Age between \\> 18\n* Both males and females.\n* Diagnosis of selected cancer type (e.g., colorectal cancer, lung cancer, genitourinary cancers, breast cancer).\n* Cancer stage III\u002F IV with or without metastasis or lymph node dissemination at the time of enrollment.\n* Unrelated patients.\n\nExclusion Criteria:\n\n* History of hematological cancer types or previous cancers, recurrent or relapse.\n* Diagnosis of inflammatory bowel diseases.\n* Pre-existing cardiovascular diseases or coronary artery diseases.\n* Confirmed treated or untreated autoimmune diseases.\n* Metabolic disorders, diabetes, or hypertension.\n* Neurological diseases.\n* Evidence of cardiac, renal, bone, or cerebral damage.\n* Presence of more than one type of malignancies.\n* Active infections or myositis.\n* Familial polyposis.\n* Alcohol or smoking habits.\n* Body mass index (BMI) \\>30.\n* Significant weight loss within the last 2 years.\n* History of surgeries.\n* Pregnancy.\n* Related patients.",{"count":76,"type":21},50,[53],"Solid tumors pose significant challenges in current therapeutic approaches. Targeted therapy has emerged as a promising avenue, aiming to enhance treatment efficacy while minimizing adverse effects. This clinical trial focuses on an innovative combination of two targeted inhibitors, Palbociclib and Bevacizumab, for their potential synergistic effects in addressing these challenging malignancies. Moreover, this study incorporates a molecular approach by considering Long Non-Coding RNAs (LncRNAs) as biomarkers. Initiating with a focus on colorectal cancer, the study aims to expand its scope to other solid tumors, including lung, breast, ovarian and other cancers. Palbociclib, a cyclin-dependent kinase 4\u002F6 (CDK4\u002F6) inhibitor, disrupts the cell cycle progression, particularly in cancer cells with specific molecular characteristics. Bevacizumab, a vascular endothelial growth factor (VEGF) inhibitor, targets angiogenesis-a critical process for tumor growth and metastasis. The rationale behind combining these agents lies in their complementary mechanisms of action, potentially leading to enhanced antitumor effects. LncRNAs have shown promise in predicting treatment response and prognosis in various cancers, providing an additional layer of precision to the treatment strategy. By elucidating the molecular basis through LncRNA analysis, the trial aims to tailor the treatment to the specific molecular profile of each patient, ultimately striving for better outcomes and improved survival rates. This novel combination therapy, coupled with a personalized biomarker-driven approach, represents a cutting-edge strategy in the pursuit of more effective and individualized treatment for solid tumors.",[80,81,82,83,84,85,86,87,88,28],"Cancer","Solid Tumor","Colorectal Cancer","Breast Cancer","Ovarian Cancer","Lung Cancer","Targeted Therapy","Chemotherapy","Immunotherapy",[90,91,92,93,94,95,96,97,98,99,80],"LncRNA","Anti-VEGF","CDK4\u002F6 inhibitor","Gene Polymorphism","Palbociclib","Bevacizumab","Inflammation","Immune Cells","Angiogenesis","Proliferative","2024-03-05",{"date":102,"type":33},"2024-03-12",{"date":104,"type":33},"2023-02-15",{"date":106,"type":21},"2027-12",{"name":108,"class":40},"Lebanese University"]